Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Pharmaceutical preparations company · L3 · FY ends Dec · -$11M FCF
$2.61
$0.19 (-6.79%)
EOD Sep 18, 2026
At 145x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from -587.04% to -675.55%, capital efficiency is deteriorating.
145.0x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$9M
▲ +35.5% YoY
Op. Margin
—
ROIC
-675.55%
▼ -88.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +27.6% YoY
Op. Cash Flow (TTM)
-$11M
▲ +27.7% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research
SourceComputed from the 10-K filed 23 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 17 Apr 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 145.0, Chemomab Therapeutics (CMMB)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
That depends on valuation and quality together, not either alone. you should weigh CMMB's valuation. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.